B&K CORP-B (02396) plans to apply for full circulation of H shares.
Qingcheng New Drug-B (02396) announced that, in accordance with the "Guidelines," the board of directors has reviewed and approved the conversion of domestic shares held by shareholders into H-shares and the listing and circulation of these H-shares on the main board of the Stock Exchange (full circulation of H-shares). Following the receipt of all relevant approvals (including the filing notice from the China Securities Regulatory Commission and the approval from the Stock Exchange) and compliance with all applicable laws, rules, and regulations, 21,681,762 domestic shares will be converted into H-shares, and the company will apply to the Stock Exchange for the listing and trading of these H-shares on the main board.
B&K CORP-B (02396) announced that, in light of the Guideline, the Board of Directors has reviewed and approved the conversion of domestic shares held by shareholders into H-shares (H-shares) and the listing and trading of such H-shares on the Main Board of the Stock Exchange (full circulation of H-shares). Following the obtaining of all relevant approvals (including the filing notice from the China Securities Regulatory Commission and the approval from the Stock Exchange) and the compliance with all applicable laws, rules, and regulations, 21,681,762 domestic shares will be converted into H-shares, and the Company will apply to the Stock Exchange for the listing and trading of these H-shares on the Main Board.
The proposed application for full circulation of the Company's unlisted shares is subject to the approval of the shareholders at the Company's second extraordinary general meeting (extraordinary general meeting) on September 4, 2026 (Friday).
Participating shareholders have agreed to grant the Board of Directors and its authorized representatives the authority to apply for the full circulation of H-shares with the China Securities Regulatory Commission, the Stock Exchange, and other relevant regulatory agencies, and to handle matters related to the full circulation of H-shares.
The proposed granting of authority to the Board of Directors and its authorized representatives to handle matters related to the application for the full circulation of the Company's unlisted shares is also subject to approval by the shareholders at the upcoming extraordinary general meeting.
Related Articles

DL HOLDINGS GP (01709) canceled 2 million shares on August 14.

TIANAN MEDICARE (00383) released its interim results, with profit attributable to shareholders reaching 47.361 million Hong Kong dollars, an increase of 295.37% year-on-year.

Applied Materials (AMAT.US) "achieved high scores" but was sold off. Analysts say the market finds the performance not impressive enough.
DL HOLDINGS GP (01709) canceled 2 million shares on August 14.

TIANAN MEDICARE (00383) released its interim results, with profit attributable to shareholders reaching 47.361 million Hong Kong dollars, an increase of 295.37% year-on-year.

Applied Materials (AMAT.US) "achieved high scores" but was sold off. Analysts say the market finds the performance not impressive enough.

RECOMMEND





